S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
New AI Stock Payouts (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
New AI Stock Payouts (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
New AI Stock Payouts (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
New AI Stock Payouts (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
New AI Stock Payouts (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
New AI Stock Payouts (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
New AI Stock Payouts (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
New AI Stock Payouts (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
NASDAQ:KZR

Kezar Life Sciences (KZR) Stock Forecast, Price & News

$1.14
-0.03 (-2.56%)
(As of 09/22/2023 ET)
Compare
Today's Range
$1.10
$1.19
50-Day Range
$1.14
$2.42
52-Week Range
$1.09
$9.00
Volume
432,572 shs
Average Volume
413,879 shs
Market Capitalization
$82.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50

Kezar Life Sciences MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
1,259.6% Upside
$15.50 Price Target
Short Interest
Healthy
3.30% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.66mentions of Kezar Life Sciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.38) to ($1.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

201st out of 963 stocks

Pharmaceutical Preparations Industry

79th out of 458 stocks


KZR stock logo

About Kezar Life Sciences (NASDAQ:KZR) Stock

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

KZR Price History

KZR Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Wells Fargo Downgrades Kezar Life Sciences
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Kezar Life Sciences (NASDAQ: KZR)
8-K: Kezar Life Sciences, Inc.
Kezar Life Sciences GAAP EPS of -$0.31
KZR Kezar Life Sciences, Inc.
Wells Fargo Reaffirms Their Buy Rating on Kezar Life Sciences (KZR)
See More Headlines
Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

KZR Company Calendar

Last Earnings
8/10/2023
Today
9/24/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KZR
Fax
N/A
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.50
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+1,259.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-68,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.95 per share

Miscellaneous

Free Float
66,950,000
Market Cap
$82.87 million
Optionable
Not Optionable
Beta
0.16
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. John Franklin FowlerMr. John Franklin Fowler (Age 50)
    Co-Founder, CEO & Director
    Comp: $919.91k
  • Dr. Christopher J. Kirk Ph.D. (Age 50)
    Co-Founder & Director
    Comp: $677.41k
  • Dr. Noreen Roth Henig M.D. (Age 58)
    Chief Medical Officer
    Comp: $722.85k
  • Dr. Jack Taunton Ph.D.
    Co-Founder
  • Mr. Marc L. BelskyMr. Marc L. Belsky (Age 68)
    CFO & Sec.
  • Ms. Gitanjali Jain
    VP of Investor Relations & External Affairs
  • Mr. Mark Schiller
    Sr. VP of Legal Affairs
  • Dr. Neel K. Anand Ph.D.
    Sr. VP of Research & Drug Discovery
  • Dr. Nick Mordwinkin Ph.D. (Age 42)
    Pharm.D., Chief Bus. Officer
  • Mr. Zung To
    Sr. VP of Clinical Devel. Operations













KZR Stock - Frequently Asked Questions

Should I buy or sell Kezar Life Sciences stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" KZR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KZR, but not buy additional shares or sell existing shares.
View KZR analyst ratings
or view top-rated stocks.

What is Kezar Life Sciences' stock price forecast for 2023?

3 brokers have issued twelve-month target prices for Kezar Life Sciences' shares. Their KZR share price forecasts range from $13.00 to $18.00. On average, they expect the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 1,259.6% from the stock's current price.
View analysts price targets for KZR
or view top-rated stocks among Wall Street analysts.

How have KZR shares performed in 2023?

Kezar Life Sciences' stock was trading at $7.04 at the beginning of the year. Since then, KZR shares have decreased by 83.8% and is now trading at $1.14.
View the best growth stocks for 2023 here
.

When is Kezar Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our KZR earnings forecast
.

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences, Inc. (NASDAQ:KZR) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by $0.01.

What other stocks do shareholders of Kezar Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL).

When did Kezar Life Sciences IPO?

(KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

What is Kezar Life Sciences' stock symbol?

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Who are Kezar Life Sciences' major shareholders?

Kezar Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Suvretta Capital Management LLC (9.86%), BlackRock Inc. (7.03%), Prosight Management LP (6.40%), Sphera Funds Management LTD. (2.74%), Granahan Investment Management LLC (2.61%) and Franklin Resources Inc. (1.92%). Insiders that own company stock include Franklin M Berger, Michael Kauffman and Morningside Venture Investment.
View institutional ownership trends
.

How do I buy shares of Kezar Life Sciences?

Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kezar Life Sciences' stock price today?

One share of KZR stock can currently be purchased for approximately $1.14.

How much money does Kezar Life Sciences make?

Kezar Life Sciences (NASDAQ:KZR) has a market capitalization of $82.87 million. The company earns $-68,240,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.

How can I contact Kezar Life Sciences?

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.kezarlifesciences.com. The company can be reached via phone at (650) 822-5600 or via email at ceconomides@kezarbio.com.

This page (NASDAQ:KZR) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -